Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View

Intersect ENT, Inc. XENT announced preliminary revenue results for third-quarter 2020 on Oct 15, 2020. Management will provide additional information in conjunction with the release of its third-quarter financial results, which is scheduled for November 2.

Intersect ENT projects third-quarter 2020 revenues in the band of $22.4-$22.8 million. The Zacks Consensus Estimate for the same is pinned at $22.6 million.

The company expects to report the strongest quarterly revenue to date of approximately $1.7 million for its SINUVA product line. Moreover, as of Sep 2020, cash and marketable securities are expected to be approximately $130 million.

The company is upbeat about the continuation of increased sequential sinus surgery procedure demand leading to strong volumes of PROPEL. Further, notable year-on-year growth of the PROPEL product line in the office setting has also been observed. The closing of the buyout deal of Fiagon AG Medical Technologies has enabled Intersect ENT to strengthen its commercial product portfolio and expand geographical footprint.


Intersect ENT expects fourth-quarter revenues to be 85-90% of fourth-quarter 2019 revenues based on the ongoing difficult elective procedure volumes and referral trends.

However, it expects to post higher revenues in 2021 compared to 2019.

Post the announcement of a downbeat Q4 guidance, the stock fell 8.3% to close at $16.23 yesterday.

Price Performance

The stock has outperformed its industry over the past six months. The stock has gained 55.6% compared with the 30.9% rise of the industry and 25.2% growth of the S&P 500 composite.

Zacks Rank and Key Picks

Currently, Intersect ENT carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are QIAGEN N.V. QGEN, Thermo Fisher Scientific Inc. TMO and Boston Scientific Corporation BSX.

QIAGEN’s long-term earnings growth rate is estimated at 17.2%. It currently flaunts a Zacks Rank #1. (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently sports a Zacks Rank #1.

Boston Scientific’s long-term earnings growth rate is estimated at 10%. The company presently carries a Zacks Rank #2 (Buy).

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
Intersect ENT, Inc. (XENT): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More